My Companies
Notification
Account
Log Out
Login
Subsidiary Innoxel commenced US commercial supply with first CMO product launched by sponsor partner Oct 20, 2026, made at Vadodara facility. Shifts Innoxel from FY26 licensing-only revenue of Rs72.4 crore to recurring supply; first of two FY27 CMO launches, with more lined into FY28.
Bharat Parenterals Board Approves ₹139 Crore Preferential Share Allotment
Bharat Parenterals Approves ₹300 Crore Biologics CDMO Facility Expansion